<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978584</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0046</org_study_id>
    <secondary_id>NCI-2021-04298</secondary_id>
    <secondary_id>2021-0046</secondary_id>
    <nct_id>NCT04978584</nct_id>
  </id_info>
  <brief_title>Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study</brief_title>
  <official_title>Smart Stop: A Phase II Trial of Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Prior to and With Standard Chemotherapy for Patients With Newly Diagnosed DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab&#xD;
      alone and in combination with chemotherapy in treating patients with newly diagnosed&#xD;
      non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasitamab are monoclonal&#xD;
      antibodies that may interfere with the ability of tumor cells to grow and spread.&#xD;
      Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for&#xD;
      cell growth. Chemotherapy drugs, such as lenalidomide, cyclophosphamide, doxorubicin, and&#xD;
      vincristine, and work in different ways to stop the growth of tumor cells, either by killing&#xD;
      the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used&#xD;
      with other drugs in the treatment of some types of cancer. Giving rituximab, lenalidomide,&#xD;
      acalabrutinib, tafasitamab alone and with combination chemotherapy may help control&#xD;
      non-germinal center diffuse large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate at the end of 4 cycles of therapy with rituximab,&#xD;
      lenalidomide, acalabrutinib, tafasitamab in patients with high risk newly diagnosed&#xD;
      non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL).&#xD;
&#xD;
      II. To determine the complete response rate at the end of 10 cycles of therapy with&#xD;
      rituximab, lenalidomide, acalabrutinib, tafasitamab and chemotherapy&#xD;
      (cyclophosphamide-hydroxydaunorubicin-oncovin-prednisone [CHOP]) in patients with high risk&#xD;
      newly diagnosed non-GCB DLBCL.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate, survival outcomes (progression free and overall&#xD;
      survival), and safety of rituximab, lenalidomide, acalabrutinib, tafasitamab and chemotherapy&#xD;
      (CHOP) in patients with high risk newly diagnosed non-GCB DLBCL.&#xD;
&#xD;
      II. To evaluate the outcomes of patients who receive 10 cycles of rituximab, lenalidomide,&#xD;
      acalabrutinib, tafasitamab with 6 concurrent cycles of CHOP in contrast to patients who&#xD;
      receive a response adapted 2 concurrent cycles of CHOP in cohort 1.&#xD;
&#xD;
      III. To evaluate the outcomes of patients who receive 10 cycles of rituximab, lenalidomide,&#xD;
      acalabrutinib, tafasitamab with 6 concurrent cycles of CHOP in contrast to patients who&#xD;
      receive a response adapted 0 concurrent cycles of CHOP in cohort 2.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the baseline and therapy induced changes in the profile of mutations, gene&#xD;
      expression, minimal residual disease circulating tumor deoxyribonucleic acid (ctDNA) levels,&#xD;
      immune cell subsets, in patients with newly diagnosed non-GCB DLBCL.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      COHORT I (SMART STOP): Patients receive rituximab intravenously (IV) over 4-6 hours on day 1,&#xD;
      acalabrutinib orally (PO) twice daily (BID) on days 1-21, lenalidomide once daily (QD) on&#xD;
      days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21&#xD;
      days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort&#xD;
      I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21,&#xD;
      lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15.&#xD;
      Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin&#xD;
      hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO&#xD;
      QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients who achieve less than a complete response,&#xD;
      receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide&#xD;
      QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Patients also receive&#xD;
      cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV&#xD;
      over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days&#xD;
      for up to 6 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 1 year, then&#xD;
      every 4 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">January 16, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At the end of 4 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab (each cycle = 21 days)</time_frame>
    <description>The response rate and exact 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>At the end of 10 cycles of therapy with rituximab, lenalidomide, acalabrutinib, tafasitamab and chemotherapy (each cycle = 21 days)</time_frame>
    <description>The response rate and exact 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>The unacceptable toxicity rate and exact 95% confidence intervals will be calculated. AE data will be summarized by frequency tables for all patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From study entry to objective disease progression or death from any cause, whichever occurs first, assessed up to 2 years post-treatment</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time between study entry and death from any cause, assessed up to 2 years post-treatment</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT I (SMART STOP): Patients receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>ACP-196</other_name>
    <other_name>Bruton Tyrosine Kinase Inhibitor ACP-196</other_name>
    <other_name>Calquence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin HCl</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>Rituximab Biosimilar SIBP-02</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tafasitamab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer</other_name>
    <other_name>Monjuvi</other_name>
    <other_name>MOR-00208</other_name>
    <other_name>MOR00208</other_name>
    <other_name>MOR208</other_name>
    <other_name>Tafasitamab-cxix</other_name>
    <other_name>XmAb5574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (uLTRA, CHOP)</arm_group_label>
    <other_name>Leurocristine</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincrystine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed diagnosis of DLBCL of the non-GCB DLBCL subtype via the&#xD;
             Hans algorithm&#xD;
&#xD;
          -  No prior treatment except a prior limited-field radiotherapy, a short course of&#xD;
             glucocorticoids =&lt; 25 mg daily of prednisone equivalent which must cease prior to day&#xD;
             1 of cycle 1, and/or 1 dose of cyclophosphamide 750 mg/m2 for an urgent lymphoma&#xD;
             related problem at diagnosis (e.g. epidural cord compression, superior vena cava&#xD;
             syndrome)&#xD;
&#xD;
          -  Patient or durable power of attorney (DPA) for healthcare must be able to understand&#xD;
             and voluntarily sign an Institutional Review Board (IRB)-approved informed consent&#xD;
             form&#xD;
&#xD;
          -  Age &gt;= 18 years at the time of signing the informed consent&#xD;
&#xD;
          -  Patients must have bi-dimensional measurable disease, as defined as radiographically&#xD;
             apparent disease with the longest dimension of &gt;= 1.5 cm&#xD;
&#xD;
          -  Patients with performance status of =&lt; 3 (3 only allowed if decline in status is&#xD;
             deemed related to lymphoma and felt potentially reversible by the treating physician)&#xD;
&#xD;
          -  Serum bilirubin &lt; 1.5 x upper limit of normal (ULN) except in patients with Gilbert's&#xD;
             syndrome as defined by &gt; 80% unconjugated bilirubin who must have a serum bilirubin of&#xD;
             &lt; 4 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x&#xD;
             ULN or &lt; 5 x ULN if hepatic metastases are present&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1000/mm^3 unless deemed related to lymphoma&#xD;
             involvement in the bone marrow and felt potentially reversible by the treating&#xD;
             physician&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm^3 unless deemed related to lymphoma involvement in the bone&#xD;
             marrow and felt potentially reversible by the treating physician&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;= 30 ml/min by Cockcroft-Gault formula&#xD;
&#xD;
          -  Patients must be willing to receive transfusions of blood products&#xD;
&#xD;
          -  All study participants must be registered into the mandatory Revlimid Risk Evaluation&#xD;
             and Mitigation Strategy (REMS) program, and be willing and able to comply with the&#xD;
             requirements of the REMS program&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum (beta-human chorionic&#xD;
             gonadotropin [beta-hCG]) at screening and must adhere to the scheduled pregnancy&#xD;
             testing as required in the Revlimid REMS program&#xD;
&#xD;
          -  Women of childbearing potential and men who are sexually active with a woman of&#xD;
             childbearing potential must be practicing a highly effective method of during and&#xD;
             after the study (12 months after study drug for women and 3 months after study drug&#xD;
             for men), consistent with local regulations regarding the use of birth control methods&#xD;
             for subjects participating in this clinical study. Men must agree to not donate sperm&#xD;
             during and for up to 3 months after their conclusion of therapy on study&#xD;
&#xD;
          -  Able to take aspirin (81 mg) daily or alternative therapy as prophylactic&#xD;
             anticoagulation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical condition including but not limited to uncontrolled hypertension,&#xD;
             uncontrolled congestive heart failure within past 6 months prior to screening (class 3&#xD;
             [moderate] or class 4 [severe] cardiac disease as defined by the New York Heart&#xD;
             Association Functional classification), uncontrolled or symptomatic arrhythmias with&#xD;
             corrected QT interval (QTc) &gt; 480 msec at screening, uncontrolled diabetes mellitus,&#xD;
             active/symptomatic coronary artery disease, chronic obstructive pulmonary disease&#xD;
             (COPD), left ventricular ejection fraction (LVEF) less than 40%, renal failure,&#xD;
             uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura active&#xD;
             infection, history of invasive fungal infection, moderate to severe hepatic disease&#xD;
             (Child Pugh class B or C), active hemorrhage, laboratory abnormality, or psychiatric&#xD;
             illness that, in the investigators opinion places the patient at unacceptable risk and&#xD;
             would prevent the subject from signing the informed consent form. Patients with&#xD;
             history of cardiac arrhythmias should have cardiac evaluation and clearance&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Known hypersensitivity to lenalidomide or thalidomide, acalabrutinib, tafasitamab,&#xD;
             rituximab, vincristine, doxorubicin, cyclophosphamide, or prednisone&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection. Hepatitis B or C serologic status:&#xD;
             subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B&#xD;
             surface antigen (HBsAg) negative will need to have a negative DNA polymerase chain&#xD;
             reaction (PCR) and must be willing to undergo DNA PCR testing during the study to be&#xD;
             eligible. Those who are HBsAg positive or hepatitis B DNA PCR positive will be&#xD;
             excluded. Subjects who are hepatitis C antibody positive will need to have a negative&#xD;
             DNA PCR result to be eligible. Those who are hepatitis C DNA PCR positive will be&#xD;
             excluded&#xD;
&#xD;
          -  All patients with known central nervous system involvement with lymphoma&#xD;
&#xD;
          -  Diagnosis of prior malignancy within the past 2 years with the exception of&#xD;
             successfully treated basal cell carcinoma, squamous cell carcinoma of the skin,&#xD;
             carcinoma &quot;in situ&quot; of the cervix or breast. History of other malignancies are allowed&#xD;
             if in remission (including prostate cancer patients in remission from radiation&#xD;
             therapy, surgery or brachytherapy), not actively being treated, with a life expectancy&#xD;
             &gt; 3 years&#xD;
&#xD;
          -  Significant neuropathy (grades 2 or grade 1 with pain) within 14 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Contraindication to any of the required concomitant drugs or supportive treatments or&#xD;
             intolerance to hydration due to preexisting pulmonary or cardiac impairment including&#xD;
             pleural effusion requiring thoracentesis or ascites requiring paracentesis not due to&#xD;
             lymphoma&#xD;
&#xD;
          -  Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30&#xD;
             days of study enrollment)&#xD;
&#xD;
          -  Patients with severe bradycardia (heart rate &lt; 40 bpm, hypotension, lightheadedness,&#xD;
             syncope)&#xD;
&#xD;
          -  Major surgery within 4 weeks of study entry, or wound that is not healed from prior&#xD;
             surgery or trauma&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to study entry&#xD;
&#xD;
          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists&#xD;
&#xD;
          -  Requires chronic treatment with strong CYP3A inhibitors&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks of study entry&#xD;
&#xD;
          -  Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand&#xD;
             disease)&#xD;
&#xD;
          -  Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic&#xD;
             purpura)&#xD;
&#xD;
          -  Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before&#xD;
             screening&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR) or activated partial&#xD;
             thromboplastin time (aPTT) (in the absence of lupus anticoagulant) &gt; 2 x ULN&#xD;
&#xD;
          -  Requires treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole,&#xD;
             lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Note: Subjects receiving&#xD;
             proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible&#xD;
             for enrollment to this study&#xD;
&#xD;
          -  Concurrent participation in another therapeutic clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Westin</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jason Westin</last_name>
      <phone>713-792-3750</phone>
      <email>jwestin@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jason Westin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Acalabrutinib</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

